Daina Graybosch
Stock Analyst at Leerink Partners
(0.85)
# 3,899
Out of 4,966 analysts
110
Total ratings
37.5%
Success rate
-10.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.70 | +185.67% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.13 | +228.64% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $23.70 | -49.37% | 1 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $10.15 | -11.33% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $84.12 | +41.46% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.57 | +27.39% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.13 | +289.86% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $69.39 | -43.80% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $29.86 | +50.70% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.49 | +2,747.26% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $1.04 | +861.54% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.16 | +316.65% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $10.59 | +258.83% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.75 | +113.33% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $100.00 | +124.00% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.12 | +1,315.09% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.31 | +1,197.71% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.41 | +538.30% | 4 | Feb 25, 2022 |
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.70
Upside: +185.67%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.13
Upside: +228.64%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $23.70
Upside: -49.37%
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $10.15
Upside: -11.33%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $84.12
Upside: +41.46%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.57
Upside: +27.39%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.13
Upside: +289.86%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $69.39
Upside: -43.80%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $29.86
Upside: +50.70%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.49
Upside: +2,747.26%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.04
Upside: +861.54%
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.16
Upside: +316.65%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $10.59
Upside: +258.83%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.75
Upside: +113.33%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $100.00
Upside: +124.00%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.12
Upside: +1,315.09%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.31
Upside: +1,197.71%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.41
Upside: +538.30%